

27-28 Ιανουαρίου 2017 Αίθουσα Εκδηλώσεων ΙΑΣΩ Μαρούσι Ι Αθήνα



ακτινοθεραπεία πρώιμου καρκίνου μαστού: νεότερα δεδομένα

Ιωάννης Γεωργακόπουλος Ακτινοθεραπευτής Ογκολόγος


δήλωση συμφερόντων

δηλώνω ότι δεν έχω (προσωπικά ή ως μέλος εργασιακής/ερευνητικής ομάδας) ή μέλος της οικογένειάς μου οποιοδήποτε οικονομικό ή άλλου είδους όφελος από τις εταιρείες/επιχειρήσεις που διοργανώνουν/χρηματοδοτούν την άνω εκδήλωση κατά τη διάρκεια των τελευταίων 4 ετών

outline

- general facts
- the evidence
 - RT: DCIS, BCT & mastectomy
 - Regional Nodal Irradiation (RNI)
- emerging data
- new treatment options of breast radiotherapy
 - hypofractionation
 - Accelerated Partial Breast Irradiation (APBI)
 - techniques of EBRT: Intensity Modulated Radiation Therapy (IMRT)
- predictive biomarkers in RT

SEER data



Cancer Statistics 2016

Leading Sites of New Cancer Cases and Deaths – 2016 Estimates

Estimated New Cases		Estimated Deaths	
Male	Female	Male	Female
Prostate	Breast	Lung & bronchus	Lung & bronchus
180,890 (21%)	246,660 (29%)	85,920 (27%)	72,160 (26%)
Lung & bronchus	Lung & bronchus	Prostate	Breast
117,920 (14%)	106,470 (13%)	26,120 (8%)	40,450 (14%)
Colon & rectum	Colon & rectum	Colon & rectum	C <mark>olon & rectum</mark>
70,820 (8%)	63,670 (8%)	26,020 (8%)	23,170 (8%)
Urinary bladder	Uterine corpus	Pancreas	Pancreas
58,950 (7%)	60,050 (7%)	21,450 (7%)	20,330 (7%)
Melanoma of the skin	Thyroid	Liver & intrahepatic bile duct	Ovary
46,870 (6%)	49,350 (6%)	18,280 (6%)	14,240 (5%)
Non-Hodgkin lymphoma	Non-Hodgkin lymphoma	Leukemia	Uterine corpus
40,170 (5%)	32,410 (4%)	14,130 (4%)	10,470 (4%)
Kidney & renal pelvis	Melanoma of the skin	Esophagus	Leukemia
39,650 (5%)	29,510 (3%)	12,720 (4%)	10,270 (4%)
Oral cavity & pharynx	Leukemia	Urinary bladder	Liver & intrahepatic bile duct
34,780 (4%)	26,050 (3%)	11,820 (4%)	8,890 (3%)
Leukemia	Pancreas	Non-Hodgkin lymphoma	Non-Hodgkin lymphoma
34,090 (4%)	25,400 (3%)	11,520 (4%)	8,630 (3%)
Liver & intrahepatic bile duct	Kidney & renal pelvis	Brain & other nervous system 9,440 (3%)	Brain & other nervous system
28,410 (3%)	23,050 (3%)		6,610 (2%)
All sites	All sites	All sites	All sites
841,390 (100%)	843,820 (100%)	314,290 (100%)	281,400 (100%)

Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder.


@2016, American Cancer Society, Inc., Surveillance Research

sentinel lymph node biopsy (SLNB)

- evaluation of nodes became "easier", less morbidity to patients and less extensive surgery
- false negative rate is similar to ALND (2-12%), likely not increased with neoadjuvantChT

Buchholz et al. 2008

very low rate of subsequent axillary recurrence (<5%)



the evidence

- role of RT in DCIS, BCT & mastectomy
- Regional Nodal Irradiation (RNI)

RT & DCIS EBCTCG meta analysis

JNCI MONOGRAPHS


Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

J Natl Cancer Inst Monogr 2010;41:162–177

- 4 randomized trials
- 3729 pts

RT & DCIS EBCTCG meta analysis



RT & DCIS conclusions EBCTCG meta analysis

- 50% benefit across the randomized trials
- RT reduced the absolute 10-year risk of any ipsilateral breast event by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P < .00001)
- effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, margin status, focality, grade, comedonecrosis, architecture, or tumor size